• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconPharmaceutical Industry

Pharmaceutical Industry

Page 38 of 100
Antibody testing will be key—once we understand what the results mean
Health
Antibody testing will be key—once we understand what the results mean
By Sy MukherjeeMay 12, 2020
Gilead remdesivir price
Newsletters
Gilead’s moral (and financial) COVID-19 conundrum
By Sy MukherjeeMay 7, 2020
Gilead-Sciences-Remdesivir
Health
Remdesivir is the first coronavirus treatment. So why is Gilead’s stock plunging?
By Sy MukherjeeMay 1, 2020
COVID forgotten communities
Newsletters
The communities we forget during COVID-19
By Sy MukherjeeApril 30, 2020
Gilead remdesivir coronavirus FDA
Health
Gilead’s remdesivir won’t be a COVID-19 miracle cure, but it’s still an important first step
By Sy MukherjeeApril 30, 2020
The coronavirus pandemic is impacting critical research into neuromuscular diseases
Health
The coronavirus pandemic is impacting critical research into neuromuscular diseases
By Sy MukherjeeApril 28, 2020
People observing social distancing rules while waiting in line outside a Walgreens Pharmacy in New York City.
Tech
How a pharmacy delivery startup has capitalized on the coronavirus pandemic
By Jeremy KahnApril 21, 2020
Big Pharma has the chance to come to the world’s rescue
Magazine
Big Pharma has the chance to come to the world’s rescue
By Sy MukherjeeApril 20, 2020
A pharmacist counts prescription drugs at the at the CentreTown Pharmacy.
Commentary
Prescription drug costs are spiraling, but price controls are the wrong solution
By Karen KerriganApril 18, 2020
The key problem to solve in the quest for coronavirus treatments
Newsletters
The key problem to solve in the quest for coronavirus treatments
By Sy MukherjeeApril 9, 2020
How the best workplaces in health care and biopharma are responding to COVID-19
Health
How the best workplaces in health care and biopharma are responding to COVID-19
By Ed FrauenheimApril 9, 2020
A researcher works on virus replication in order to develop a vaccine against the coronavirus COVID-19, in Belo Horizonte, state of Minas Gerais, Brazil, on March 26, 2020. - The Ministry of Health convened The Technological Vaccine Center of the Federal University of Minas Gerais laboratory to conduct research on the coronavirus COVID-19 in order to diagnose, test and develop a vaccine. (Photo by Douglas MAGNO / AFP) (Photo by DOUGLAS MAGNO/AFP via Getty Images)
Commentary
These pharmaceutical companies are the top inventors and innovators
By IDEA PharmaApril 6, 2020
Johnson & Johnson hopes to have its promising coronavirus vaccine approved by early 2021
Health
Johnson & Johnson hopes to have its promising coronavirus vaccine approved by early 2021
By Sy MukherjeeMarch 30, 2020
Coronavirus Glass Sculpture
Commentary
The coronavirus pandemic has shattered the status quo on drug development. We should build on that
By E. Richard GoldMarch 26, 2020
Moderna coronavirus vaccine
Newsletters
The first U.S. coronavirus vaccine trials have begun
By Sy MukherjeeMarch 17, 2020
1...
  • 36
  • 37
  • 38
  • 39
  • 40
...100
Most Popular
Real Estate
The Pentagon and Britain are bracing for the power to go out. The ultrawealthy got there first, with backup generators, escape homes, and stockpilesplaceholder alt text
By Sydney LakeOctober 30, 2026
Europe
‘It’s only when you see 49-ton trucks in China running on batteries that you realize how serious electrification is’: Octopus Energy CEO Greg Jackson on Europe’s incumbency problemplaceholder alt text
By Kamal AhmedOctober 30, 2026
Politics
Tesla and 113 other companies paid no current federal income tax, but they still aren’t the biggest threats to the federal deficit, think tank warnsplaceholder alt text
By Sasha RogelbergOctober 30, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • TikTok icon
  • YouTube icon

    © 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
    FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.